S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Bank Accounts: Frozen! (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Fed's Shocking New Plan to Control Your Money (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
BREAKING: Tiny biotech successfully treats blindness (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Bank Accounts: Frozen! (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Fed's Shocking New Plan to Control Your Money (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
BREAKING: Tiny biotech successfully treats blindness (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Bank Accounts: Frozen! (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Fed's Shocking New Plan to Control Your Money (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
BREAKING: Tiny biotech successfully treats blindness (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Bank Accounts: Frozen! (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Fed's Shocking New Plan to Control Your Money (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
BREAKING: Tiny biotech successfully treats blindness (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
NASDAQ:NBTX

Nanobiotix - NBTX Stock Forecast, Price & News

$3.45
0.00 (0.00%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.45
$3.45
50-Day Range
$3.45
$4.49
52-Week Range
$2.32
$7.97
Volume
N/A
Average Volume
1,942 shs
Market Capitalization
$120.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NBTX stock logo

About Nanobiotix (NASDAQ:NBTX) Stock

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Receive NBTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nanobiotix and its competitors with MarketBeat's FREE daily newsletter.

NBTX Stock News Headlines

Nanobiotix (NBTX) to Release Quarterly Earnings on Tuesday
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Voting Rights and Shares Capital of the Company
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
See More Headlines
Receive NBTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nanobiotix and its competitors with MarketBeat's FREE daily newsletter.

NBTX Company Calendar

Today
3/28/2023
Next Earnings (Confirmed)
3/28/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NBTX
Fax
N/A
Employees
98
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.13 million
Book Value
$0.91 per share

Miscellaneous

Free Float
33,673,000
Market Cap
$120.34 million
Optionable
Not Optionable
Beta
0.14

Key Executives

  • Mr. Laurent Levy Ph.D. (Age 49)
    Co-Founder, Pres of the Exec. Board & CEO
    Comp: $585.36k
  • Mr. Bart Van Rhijn
    CFO & Member of Exec. Board
  • Ms. Anne-Juliette Hermant M.A. (Age 48)
    Chief People Officer & Member of Exec. Board
    Comp: $304.33k
  • Prof. Para Prasad Ph.D. (Age 77)
    Co-Founder and Member of Scientific Board
  • Mr. Earl J. Bergey Ph.d. (Age 67)
    Co-Founder
  • Mr. Alain Dostie
    Chief Operating Officer
  • Ms. Kathryn M. McNeil (Age 47)
    Sr. VP of Investor Relations
  • Mr. Brandon Owens
    VP of Strategic Marketing & Corp. Communication
  • Ms. Elsa Borghi
    Head of Innovation & Drug Discovery
  • Ms. Sarah Gaubert
    Head of Communication & Public Affairs Department













NBTX Stock - Frequently Asked Questions

How have NBTX shares performed in 2023?

Nanobiotix's stock was trading at $3.67 at the beginning of 2023. Since then, NBTX shares have decreased by 6.0% and is now trading at $3.45.
View the best growth stocks for 2023 here
.

When is Nanobiotix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023.
View our NBTX earnings forecast
.

How can I listen to Nanobiotix's earnings call?

Nanobiotix will be holding an earnings conference call on Wednesday, March 29th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-689-8573.

When did Nanobiotix IPO?

(NBTX) raised $95 million in an initial public offering on Friday, December 11th 2020. The company issued 6,500,000 shares at a price of $14.69 per share. Jefferies, Evercore ISI, UBS Investment Bank and Gilbert DuPont served as the underwriters for the IPO.

What is Nanobiotix's stock symbol?

Nanobiotix trades on the NASDAQ under the ticker symbol "NBTX."

How do I buy shares of Nanobiotix?

Shares of NBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nanobiotix's stock price today?

One share of NBTX stock can currently be purchased for approximately $3.45.

How much money does Nanobiotix make?

Nanobiotix (NASDAQ:NBTX) has a market capitalization of $120.34 million and generates $3.13 million in revenue each year.

How can I contact Nanobiotix?

The official website for the company is www.nanobiotix.com. The company can be reached via phone at 33-1-40-26-04-70.

This page (NASDAQ:NBTX) was last updated on 3/28/2023 by MarketBeat.com Staff